Cite
MLA Citation
V. Bücklein et al.. “P1447: INFERIOR OUTCOMES OF EU VS. US PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CD19 CAR T-CELL THERAPY ARE IMPACTED BY BASELINE RISK FACTORS AND CAR PRODUCT CHOICE.” HemaSphere, vol. 6, n.d., pp. 1330–1331. http://access.bl.uk/ark:/81055/vdc_100159757569.0x000008